Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Molina Healthcare’s (NYSE:MOH) Q1: Beats On Revenue
MOH Cover Image
Molina Healthcare’s (NYSE:MOH) Q1: Beats On Revenue

In This Article:

Healthcare insurance company Molina Healthcare (NYSE:MOH) announced better-than-expected revenue in Q1 CY2025, with sales up 12.2% year on year to $11.15 billion. Its non-GAAP profit of $6.08 per share was 2.1% above analysts’ consensus estimates.

Is now the time to buy Molina Healthcare? Find out in our full research report.

Molina Healthcare (MOH) Q1 CY2025 Highlights:

  • Revenue: $11.15 billion vs analyst estimates of $10.86 billion (12.2% year-on-year growth, 2.6% beat)

  • Adjusted EPS: $6.08 vs analyst estimates of $5.96 (2.1% beat)

  • Adjusted EBITDA: $508 million vs analyst estimates of $520.8 million (4.6% margin, 2.5% miss)

  • Adjusted EPS guidance for the full year is $24.50 at the midpoint, roughly in line with what analysts were expecting

  • Operating Margin: 3.9%, in line with the same quarter last year

  • Free Cash Flow Margin: 1.5%, similar to the same quarter last year

  • Customers: 5.8 million, up from 5.54 million in the previous quarter

  • Market Capitalization: $17.57 billion

Company Overview

Founded in 1980 as a provider for underserved communities in Southern California, Molina Healthcare (NYSE:MOH) provides managed healthcare services primarily to low-income individuals through Medicaid, Medicare, and Marketplace insurance programs across 21 states.

Health Insurance Providers

Upfront premiums collected by health insurers lead to reliable revenue, but profitability ultimately depends on accurate risk assessments and the ability to control medical costs. Health insurers are also highly sensitive to regulatory changes and economic conditions such as unemployment. Going forward, the industry faces tailwinds from an aging population, increasing demand for personalized healthcare services, and advancements in data analytics to improve cost management. However, continued regulatory scrutiny on pricing practices, the potential for government-led reforms such as expanded public healthcare options, and inflation in medical costs could add volatility to margins. One big debate among investors is the long-term impact of AI and whether it will help underwriting, fraud detection, and claims processing or whether it may wade into ethical grey areas like reinforcing biases and widening disparities in medical care.

Sales Growth

Examining a company’s long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Luckily, Molina Healthcare’s sales grew at an impressive 19.4% compounded annual growth rate over the last five years. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis.